4/A: Structure Therapeutics Executive Corrects Stock Option Exercise Price in Amended SEC Filing

Mark Allen Bach, Chief Medical Officer of Structure Therapeutics Inc., files an amendment to a Form 4, correcting the exercise price of stock options to reflect the price of Ordinary Shares rather than American Depositary Shares (ADSs).

Summary

• Mark Allen Bach, the Chief Medical Officer of Structure Therapeutics Inc., filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price of a stock option granted on March 15, 2024.
• The original filing incorrectly stated the exercise price as that of American Depositary Shares (ADSs) instead of Ordinary Shares.
• The corrected exercise price is $11.75 per Ordinary Share.
• The stock option grants the right to buy 65,352 Ordinary Shares.
• 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
• Each ADS represents three Ordinary Shares of the Issuer.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company, but transparency is generally viewed favorably.

Industry Context

This filing is a routine disclosure related to executive compensation and stock options, common in publicly traded companies. It provides transparency into the equity-based compensation of key executives.

Stakeholder Impact

• The correction of the stock option exercise price ensures accurate reporting to shareholders and potential investors.

Key Dates